Ketazocine
| Ketazocine | |
|---|---|
| 220px | |
| 200px | |
| IUPAC name | (2R,6S,11S)-3-(cyclopropylmethyl)-3,4,5, 6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6- methano-3-benzazocin-1(2H)-one |
| Identifiers | |
| CAS number | |
| PubChem | |
| MeSH | |
| Properties | |
| Molecular formula | C18H23NO2 |
| Molar mass | 285.381 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
Ketazocine (INN) (Ketocyclazocine) is a cyclazocine derivative used in opioid receptor research. Ketocyclazocine is an exogenous (not naturally produced by the body) opioid that binds to the kappa opioid receptor.
Activation of this receptor causes a decrease in pain sensations and increased sleepiness but can also cause psychological symptoms such as feelings of unease, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous (produced by the body) substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)
Unlike other opioids, substances that only bind to the kappa receptor theoretically do not impair the normal drive to breathe.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies